D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
77,500
-8,300 (-9.67%)
At close: Feb 6, 2026
504.29%
Market Cap3.37T +492.3%
Revenue (ttm)8.36B +2.2%
Net Income-34.76B
EPS-845.57
Shares Out43.54M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,042,111
Average Volume1,167,679
Open79,700
Previous Close85,800
Day's Range75,500 - 82,900
52-Week Range10,125 - 113,700
Betan/a
RSI36.84
Earnings DateMar 20, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements